Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8667325 | 0.75 | PNP (0.38) | — | |
| SCHEMBL9470349 | 0.66 | LMNA (0.39) | — | |
| SCHEMBL3845982 | 0.63 | — | — | |
| SCHEMBL8340807 | 0.62 | PNP (0.33) | — | |
| SCHEMBL8340810 | 0.62 | ADORA3 (0.47) | — | |
| SCHEMBL8326031 | 0.58 | RXFP1 (0.39) | RXFP1 | |
| SCHEMBL9471538 | 0.58 | CRBN (0.39) | — | |
| SCHEMBL8848920 | 0.57 | — | — | |
| SCHEMBL3694629 | 0.55 | PNP (0.38) | — | |
| SCHEMBL12605552 | 0.55 | CDK4 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592397-B2 | Compositions and methods for combination antiviral therapy | GILEAD SCIENCES, INC. (US) | 2013-11-26 | — | — | US | disclosed |
| EP-1828145-A4 | 2' AND 3' - SUBSTITUTED CYCLOBUTYL NUCLEOSIDE ANALOGS FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | UNIV EMORY (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20090143314-A1 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY | GILEAD SCIENCES, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| EP-1828145-A2 | 2' AND 3' - SUBSTITUTED CYCLOBUTYL NUCLEOSIDE ANALOGS FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | EMORY UNIVERSITY (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20060246130-A1 | Compositions and methods for combination antiviral therapy | GILEAD SCIENCES, INC. | 2006-11-02 | — | — | US | disclosed |
| WO-2006063281-A2 | 2' AND 3' - SUBSTITUTED CYCLOBUTYL NUCLEOSIDE ANALOGS FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | EMORY UNIVERSITY (US) | 2006-06-15 | — | — | WO | disclosed |
| US-6500663-B1 | TREATING A SUBJECT AFFLICTED WITH A KAPOSI'S SARCOMA CAUSED BY KAPOSI'S SARCOMA ASSOCIATED HERPESVIRUS WHICH COMPRISES ADMINISTERING A NUCLEOSIDE ANALOG OR AN ANTISENSE NUCLEIC ACID | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2002-12-31 | — | — | US | disclosed |
| EP-0934333-A4 | UNIQUE ASSOCIATED KAPOSI'S SARCOMA VIRUS SEQUENCES AND USES THEREOF | UNIV COLUMBIA (US) | 1999-11-03 | — | — | EP | disclosed |
| EP-0934333-A1 | UNIQUE ASSOCIATED KAPOSI'S SARCOMA VIRUS SEQUENCES AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 1999-08-11 | — | — | EP | disclosed |
| EP-0891374-A4 | UNIQUE ASSOCIATED KAPOSI'S SARCOMA VIRUS SEQUENCES AND USES THEREOF | UNIV COLUMBIA (US) | 1999-04-07 | — | — | EP | disclosed |
| EP-0891374-A1 | UNIQUE ASSOCIATED KAPOSI'S SARCOMA VIRUS SEQUENCES AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 1999-01-20 | — | — | EP | disclosed |
| WO-1998004576-A1 | UNIQUE ASSOCIATED KAPOSI'S SARCOMA VIRUS SEQUENCES AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1998-02-05 | — | — | WO | disclosed |
| WO-1997027208-A1 | UNIQUE ASSOCIATED KAPOSI'S SARCOMA VIRUS SEQUENCES AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1997-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143314-A1 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY | DCTD, TYMP, TYMS | RXFP1 4004/4885 |
| US-20060246130-A1 | Compositions and methods for combination antiviral therapy | DCTD, TYMP, MTAP | RXFP1 4189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.